Japanese clinical practice guidelines for IgA nephropathy: Difference from KDIGO guidelines

Kazuo Takahashi, Ryohei Yamamoto, Yukio Yuzawa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In Japan, the Progressive Renal Dysfunction Research Group of the Ministry of Health, Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) developed the Clinical Practice Guides for Immunoglobulin A (IgA) Nephropathy (IgAN) for the first time in 1995. Thereafter, they published its second version in 2002 and third version in 2011. Meanwhile, the Kidney Disease: Improving Global Outcomes (KDIGO) published the Clinical Practice Guidelines for Glomerulonephritis in 2011. The Progressive Renal Dysfunction Research Group of MHLW and JSN developed the Clinical Practice Guidelines for Immunoglobulin A Nephropathy 2014 as an evidence-based guideline to make it more suitable for clinical practice in Japan. In this article, we describe the outlines of the Japanese guidelines and the differences between the Japanese and KDIGO guidelines. These practical guidelines provide evidence-based optimum treatment and will lead to new clinical trials raised from clinical questions in IgAN.

Original languageEnglish
Title of host publicationPathogenesis and Treatment in IgA Nephropathy
Subtitle of host publicationAn International Comparison
PublisherSpringer Japan
Pages251-262
Number of pages12
ISBN (Electronic)9784431555889
ISBN (Print)9784431555872
DOIs
Publication statusPublished - 10-03-2016

Fingerprint

IGA Glomerulonephritis
Kidney Diseases
Practice Guidelines
Guidelines
Nephrology
Japan
Kidney
Health
Glomerulonephritis
Research
Immunoglobulin A
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Takahashi, K., Yamamoto, R., & Yuzawa, Y. (2016). Japanese clinical practice guidelines for IgA nephropathy: Difference from KDIGO guidelines. In Pathogenesis and Treatment in IgA Nephropathy: An International Comparison (pp. 251-262). Springer Japan. https://doi.org/10.1007/978-4-431-55588-9_15
Takahashi, Kazuo ; Yamamoto, Ryohei ; Yuzawa, Yukio. / Japanese clinical practice guidelines for IgA nephropathy : Difference from KDIGO guidelines. Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan, 2016. pp. 251-262
@inbook{1931ee849acf4fd48ed722e9f1040d06,
title = "Japanese clinical practice guidelines for IgA nephropathy: Difference from KDIGO guidelines",
abstract = "In Japan, the Progressive Renal Dysfunction Research Group of the Ministry of Health, Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) developed the Clinical Practice Guides for Immunoglobulin A (IgA) Nephropathy (IgAN) for the first time in 1995. Thereafter, they published its second version in 2002 and third version in 2011. Meanwhile, the Kidney Disease: Improving Global Outcomes (KDIGO) published the Clinical Practice Guidelines for Glomerulonephritis in 2011. The Progressive Renal Dysfunction Research Group of MHLW and JSN developed the Clinical Practice Guidelines for Immunoglobulin A Nephropathy 2014 as an evidence-based guideline to make it more suitable for clinical practice in Japan. In this article, we describe the outlines of the Japanese guidelines and the differences between the Japanese and KDIGO guidelines. These practical guidelines provide evidence-based optimum treatment and will lead to new clinical trials raised from clinical questions in IgAN.",
author = "Kazuo Takahashi and Ryohei Yamamoto and Yukio Yuzawa",
year = "2016",
month = "3",
day = "10",
doi = "10.1007/978-4-431-55588-9_15",
language = "English",
isbn = "9784431555872",
pages = "251--262",
booktitle = "Pathogenesis and Treatment in IgA Nephropathy",
publisher = "Springer Japan",
address = "Japan",

}

Takahashi, K, Yamamoto, R & Yuzawa, Y 2016, Japanese clinical practice guidelines for IgA nephropathy: Difference from KDIGO guidelines. in Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan, pp. 251-262. https://doi.org/10.1007/978-4-431-55588-9_15

Japanese clinical practice guidelines for IgA nephropathy : Difference from KDIGO guidelines. / Takahashi, Kazuo; Yamamoto, Ryohei; Yuzawa, Yukio.

Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan, 2016. p. 251-262.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Japanese clinical practice guidelines for IgA nephropathy

T2 - Difference from KDIGO guidelines

AU - Takahashi, Kazuo

AU - Yamamoto, Ryohei

AU - Yuzawa, Yukio

PY - 2016/3/10

Y1 - 2016/3/10

N2 - In Japan, the Progressive Renal Dysfunction Research Group of the Ministry of Health, Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) developed the Clinical Practice Guides for Immunoglobulin A (IgA) Nephropathy (IgAN) for the first time in 1995. Thereafter, they published its second version in 2002 and third version in 2011. Meanwhile, the Kidney Disease: Improving Global Outcomes (KDIGO) published the Clinical Practice Guidelines for Glomerulonephritis in 2011. The Progressive Renal Dysfunction Research Group of MHLW and JSN developed the Clinical Practice Guidelines for Immunoglobulin A Nephropathy 2014 as an evidence-based guideline to make it more suitable for clinical practice in Japan. In this article, we describe the outlines of the Japanese guidelines and the differences between the Japanese and KDIGO guidelines. These practical guidelines provide evidence-based optimum treatment and will lead to new clinical trials raised from clinical questions in IgAN.

AB - In Japan, the Progressive Renal Dysfunction Research Group of the Ministry of Health, Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN) developed the Clinical Practice Guides for Immunoglobulin A (IgA) Nephropathy (IgAN) for the first time in 1995. Thereafter, they published its second version in 2002 and third version in 2011. Meanwhile, the Kidney Disease: Improving Global Outcomes (KDIGO) published the Clinical Practice Guidelines for Glomerulonephritis in 2011. The Progressive Renal Dysfunction Research Group of MHLW and JSN developed the Clinical Practice Guidelines for Immunoglobulin A Nephropathy 2014 as an evidence-based guideline to make it more suitable for clinical practice in Japan. In this article, we describe the outlines of the Japanese guidelines and the differences between the Japanese and KDIGO guidelines. These practical guidelines provide evidence-based optimum treatment and will lead to new clinical trials raised from clinical questions in IgAN.

UR - http://www.scopus.com/inward/record.url?scp=85028577866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028577866&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55588-9_15

DO - 10.1007/978-4-431-55588-9_15

M3 - Chapter

AN - SCOPUS:85028577866

SN - 9784431555872

SP - 251

EP - 262

BT - Pathogenesis and Treatment in IgA Nephropathy

PB - Springer Japan

ER -

Takahashi K, Yamamoto R, Yuzawa Y. Japanese clinical practice guidelines for IgA nephropathy: Difference from KDIGO guidelines. In Pathogenesis and Treatment in IgA Nephropathy: An International Comparison. Springer Japan. 2016. p. 251-262 https://doi.org/10.1007/978-4-431-55588-9_15